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Summary 
In the last few decades we have witnessed a great advancement in the treatment of rectal 
carcinoma. This advancement has partly been enabled by the development of new surgical tech-
niques, magnetic resonance imaging as an optimal diagnostic tool and of new histopathological 
techniques for resected specimen evaluation. Other important contributions include the develo-
pment of sophisticated radiotherapy treatment techniques which, applied with new cytostatics 
and smart drugs, induce a better tumor response while reducing toxicity. Although each discipli-
ne has contributed to a better understanding of the disease, it is the multidisciplinary approach 
that has yielded success in treatment so far.
Keywords: neoadjuvant therapy; short course radiotherapy; long course radiotherapy; con-
comitant chemotherapy; pathologic complete response. 
INTRODUCTION
Carcinoma of the rectum, together with colon cancer, is the third most common 
malignancy. It appears frequently and at the same rate in women and men - 9.4% of 
the newly detected patients and 7.9% of all causes of death from malignant disease.
In the last two decades we have witnessed great changes in the detection and 
treatment of rectal carcinoma. These changes have been mainly founded on im-
provements in the fields of preoperative classification of the disease, surgical te-
chniques, histopathological evaluation of the resected specimen and application of 
multidisciplinary procedures with the aim of ensuring a better long-term outcome 
for patients. A crucially important concept is the “mesorectal excision” based on 
a precise dissection of the anatomical plane surrounding the mesorectal adipose 
tissue. Numerous studies, including randomized controlled trials, clearly show the 
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importance of the total mesorectal excision as a surgical technique which has led to 
a statistically significant decrease in local recurrence rates in tertiary referral hos-
pitals. Surgery has been so far the most important therapeutic procedure in the tre-
atment of rectal cancer, although multidisciplinary and individualized approaches 
have been gaining more significance recently. Magnetic resonance imaging (MRI) 
has become the primary diagnostic tool for preoperative evaluation of patients due 
to its ability to precisely display the mesorectal fascia. Establishing of a tumor in-
filtration has been suggested as a mandatory stage in the radiological processing of 
every patient. The development of radiological classification of rectal carcinoma is 
closely connected with changes in the histopathological evaluation techniques for 
measuring the microscopic distance of the tumor from the circumferential resec-
tion margin (CRM) of the resected specimen. CRM represents the distance from 
the edge of the soft tissue preparation/soft tissue margin to the deepest penetration 
of the tumor. After the operation, the description of the CRM margin presents an 
essential component of the pathological finding. This procedure provides surgeons 
with the choice of the optimal surgical plane. Low-lying tumors pose a major chall-
enge for successful treatment. The restricted space between the bony structures of 
the pelvis reduces the possibility of radical surgical removal, resulting in a high risk 
of local recurrence [1]. Most cases of recurrence (85%) appear within the first three 
years after the end of the treatment [2]. 
THE ROLE OF RADIOTHERAPY IN THE RECTAL CANCER TREATMENT 
Research on modalities and timing of chemoradiotherapy application departs 
from the science-based facts about better local control and prolonged survival in 
patients with T3-4 N+ tumors treated with adjuvant chemoradiotherapy (NSABP 
R – 01 [3] and NSABP R – 02 [4]. 
Multiple European phase III randomized studies have assessed the role of ra-
diotherapy and chemotherapy in the neoadjuvant treatment of rectal cancer. Based 
on the results of these studies, neoadjuvant radiotherapy was accepted by ESTRO 
in 2007 as a standard approach in the treatment of patients with locally advanced 
disease (T3-4 N+). Preoperative treatment benefits range from the reduction of the 
tumor, to pathologic complete regression/pathologic complete response (pCR) in 10-
25% of patients. Radical local resection is facilitated and the likelihood of a margin-
free tumor resection is increased. 
Short course preoperative radiotherapy (SCPRT) has proved superior in decreasing 
local recurrence in operable tumors compared to adjuvant radiotherapy (5% vs. 11%) 
[5]. Studies comparing long and short course preoperative radiotherapy have shown no 
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difference in the local recurrence rate, total survival rate, dissemination risk and 
late toxicity between these two groups [6]. Less side effects and fewer treatment 
fractions make SCPRT cheaper and more accessible than the adjuvant chemoradio-
therapy. The SCPRT is optimal in the treatment of T3 tumors located in the middle 
third of the rectum with a negative CRM. In “potentially” operable, CRM positive or 
low-lying tumors concomitant preoperative chemoradiotherapy based on long course 
schedule (LC) is the preferred choice.
Following the first application of short course preoperative radiotherapy in En-
gland, two major studies have confirmed its significance in the treatment of rectal 
cancer. Between 1980 and 1993, more than 2,000 patients were included in the Swe-
dish Rectal Cancer trials, of which the most important one is the Swedish Rectal 
Trial 1 conducted between 1987 and 1990 [7].
The Swedish study showed a statistically significant decreased local recurrence 
rate in short course radiotherapy followed by surgery compared to surgery alone. 
The local recurrence rate decreased from 27% to 11% (p<0.001), 5-year survival rate 
increased from 48% with surgery alone to 58% with SCRT followed by surgery (p = 
0.004). A recent report confirmed that the benefits shown were sustained after a 13-
year follow-up. The applied radiation benefit (a reduced local recurrence rate) was 
briefly called into question after published results of only 8.2% local recurrence in 
patients treated with the total mesorectal excision technique (TME) only. A crucial 
question which arose in that period was whether a short course radiotherapy only 
compensated the poor radiotherapy technique. For that reason further studies were 
conducted to examine the role of short course radiotherapy combined with total me-
sorectal excision.
The study from the Dutch Colorectal Cancer Group randomized patients into a 
group subjected to preoperative pelvic irradiation at a dose of 5x5 Gy and a control 
group operated without any irradiation. It was shown that the local recurrence rate 
after 5 years could be further reduced to 2.4 % even after TME (p = 0.001) [8]. Unlike 
the Swedish study, the Dutch study did not show any improvement in the total sur-
vival rate by adding radiotherapy to the treatment. 
The study from the Medical Research Council CR07 compared the application 
of SCRT and surgery to initial surgery and postoperative chemoradiotherapy, the 
latter being limited to patients with the tumor found on the circumferential resec-
tion margin. The percentage of local recurrence was reduced by almost half – from 
11% using TME only to 5% by adding SCRT before TME. In this study, pathologists 
assessed the plane obtained in the resected specimen (mesorectal, intramesorec-
tal and muscularis propria). A larger percent of local recurrence was found in the 
muscularis propria plane, while a decrease in local recurrence was observed in all 
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three planes when SCPRT was applied [5]. Later studies have confirmed the success 
of preoperative radiotherapy in reducing local recurrence, even in cases with the 
optimized surgical technique.
LITERATURE EVIDENCE SUPPORTING APPLICATION OF LONG COURSE 
PREOPERATIVE RADIOCHEMOTHERAPY 
This approach was initially developed as a postoperative adjuvant therapy and 
introduced in Northern American official guidelines since 1990 when adjuvant po-
stoperative chemotherapy and concomitant chemoradiotherapy with 5-FU were re-
commended for all patients with T3-4 or node-positive rectal cancer.
In Europe, two phase III randomized studies were conducted between 1993 and 
2003, comparing long course preoperative radiotherapy (45 Gy in 25 fractions) to 
concurrent 5-FU/LV with the same radiotherapy protocol. The studies mentioned 
were FFCD 9203 and EORTC 22921 [9,10]. Both have shown that the addition of con-
current 5-FU/LV causes an acceptable increase of acute toxicity and leads to the pa-
thologic down-staging of the disease. Furthermore, both studies have displayed a 
decrease in local recurrence rate from 15% to 8-10%, with no difference in the dise-
ase free or overall survival.
A third study was conducted by GRCSG (German Rectal Cancer Study Group). 
According to the treatment results in 823 patients with T3-4 or N+ rectal cancer 5-year 
survival was 76% and 74% in the groups treated before or after the operation. Local 
recurrence was 6% in the group with neoadjuvant radiochemotherapy and 13% in 
the control group with adjuvant radiochemotherapy (p=0.006). Significantly fewer 
side effects grade 3 and 4 were in neoadjuvant group ‒ 27% than in the adjuvant 
group ‒ 40% (p=0.001) [11]. Later published results of the same group (GRCSG) after 
a 11-year follow-up kept the level of statistical significance in terms of local recu-
rrence, with no impact on the length of survival [12].
These results have led to significant changes, the consequence of which is a shift 
in treatment from postoperative to preoperative chemoradiotherapy. This treatment 
strategy has been further supported by the results of the NSABP R-03 study.
In that trial, a similar comparison of pre- and postoperative radiotherapy has 
been carried out which enrolled 267 patients [13]. After a median follow-up of 8.4 ye-
ars, a significantly better 5-year disease free survival (DFS) in neoadjuvantly treated 
patients was observed ‒ 64.7 % versus 53.4% (p=0.011). There was no difference in 
overall survival (OS) of 74.5% vs. 65.6% (p=0.065).
This treatment is widely applied today. Concurrent chemotherapy can be based 
on the combination of 5-FU/LV or on oral fluoropyrimidines, such as capecitabine.
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DIRECT COMPARISION OF SHORT COURSE VS. LONG COURSE 
RADIOTHERAPY
Two studies have compared short course preoperative radiotherapy with long co-
urse preoperative chemoradiotherapy. Bujko et al. have compared the outcomes of a 
short-course (5x5 Gy) and long-course (28x1,8 Gy) neoadjuvant chemoradiotherapy. 
The 5-year local recurrence rates were 9% and 14% (p = 0.17) for SCPRT and CRT, 
respectively. The rate of late complications did not differ significantly – 10% (short-
course) vs. 7 % (long-course) [14]. The Trans Tasman Group (TROG) trial also rando-
mized 326 patients with resectable rectal cancer to receive either SCPRT or preope-
rative CRT to compare the local recurrence rates [6]. Between these two groups no 
differences were noted in the occurrence of local recurrence, overall survival rate, 
dissemination and late toxicity.
The radiation technique necessary to reduce the early and late side effects risk 
has recently not significantly changed. It assumes radiation simulation with the pa-
tient in prone position placed on the table with a hole for the abdomen. The small 
gut should be shown by applying the contrast media and modern tools for radiation 
planning should be used (3-D).
OXALIPLATIN, IRINOTECAN AND BIOLOGICAL AGENTS IN  
PREOPERATIVE CHEMORADIOTHERAPY OF RECTAL CANCER
5-FU is fundamental in all chemoradiotherapy and adjuvant chemotherapy pro-
tocols used in the treatment of rectal cancer. It is believed that the effectiveness of 
these protocols can be improved by introducing new drugs successful in the tre-
atment of colorectal cancer and that this can lead to a better control of distal me-
tastases, as well as a higher survival rate. Oxaliplatin administered together with 
5-FU and leucovorin has a significant effect in the treatment of metastatic colorectal 
cancer. This finding has caused an interest in its use as a part of a combined protocol 
for the treatment of locally advanced disease.
Aschele et al. have conducted a study on the synergistic effect of oxaliplatin 
(STAR-01) in 747 patients in Italy [15]. The pathological complete response rate was 
the same (16%) in two randomized groups, and the rate of grade 3 and 4 adverse re-
actions was 24% in the group with oxaliplatin and 8% in the control group (p=0.001). 
In the ACCORD study, 598 patients with T3-4 N+ rectal cancer were randomized 
into groups of 45 Gy of radiation in 25 fractions with concomitant capecitabine or 50 
Gy in 25 fractions with concomitant capecitabine and oxaliplatin. Complete patho-
logical response was recorded in 19.2% of patients receiving oxaliplatin vs. 13.9% in 
the control group (p=0.09), while grade 3 or 4 toxicity was observed in 25% vs. 11% 
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in the control group (p=0.001). There was no difference in sphincter preservation 
during surgery (75% vs. 78%) [16]. Somewhat conflicting results were reported in a 
study performed by Rödel et al. CAO/ARO/AIO-04 where 1236 patients were rando-
mized into groups of neoadjuvant radiotherapy with 5-FU or 5-FU with oxaliplatin 
[17]. A significantly higher complete pathological regression rate was recorded (17% 
vs. 13%) in the control group (p=0.038) with no significant difference in the incidence 
of grade 3 and 4 side effects.
Although the incidence of acute side effects was monitored in most studies, they 
cause only short-term discomfort and stop spontaneously or with symptomatic me-
dication completely. Based on the results of these studies, the adding of oxaliplatin 
does not contribute to the reduction of the primary rectal tumor in neoadjuvant 
chemoradiotherapy, but increases the rate of acute side effects [15-17]. Currently, the 
application of oxaliplatin in the neoadjuvant treatment setting with radiation is not 
warranted outside of research protocols.Therefore is necessary to wait and observe 
the results from these studies, particularly in terms of disease free survival (DFS).
Irinotecan administered together with 5-FU and leucovorin has a significant ef-
fect in the treatment of metastatic colorectal cancer and it improves both progressi-
on-free and overall survival [18]. This finding, the same as in the use of oxalipatin, 
has resulted in an interest in developing its use as part of a combined protocol for 
the treatment of a locally advanced disease. Iles et al. have conducted a study on the 
synergistic effect of irinotecan and 5-flourouracil (NWCOG-1) on 31 patients with 
inoperable locally advanced rectal cancer [19]. Preoperative restaging with MRI 
showed a reduction in tumor stage in 79% of patients after the treatment, while 81% 
had clear circumferential resection margins. The regimen was well tolerated.
Gollins et al. have conducted a study on the synergistic effect of capecitabine 
and irinotecan (NWCOG-2) on 110 patients with MRI-defined locally advanced rec-
tal cancer. The regimen appears more effective in down-staging by using a single-
agent, fluoropyrimidine, than historical reports suggest. The pathologic complete 
response rate was 22% and the study showed a strong correlation between the ef-
ficacy of CRT down-staging as expressed by reduction of the histologic stage to 
ypCR or microfoci and superior overall survival [20]. Currently, the application of 
irinotecan in the neoadjuvant treatment setting with radiation is being further in-
vestigated. 
The integration of EGFR and VEGF targeting therapies in preoperative chemo-
radiation protocols was based on vast theoretical knowledge, relatively good results 
of preclinical studies and significant effect in the treatment of metastatic colorectal 
cancer. Phase II studies showed no clear clinical benefit and detected a problem in 
the use of pCR as the final endpoint [21-23]. 
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The rate of tumor complete response rate (pCR) was somewhat higher in bevaci-
zumab containing protocols, but the incidence of general, bevacizumab-related ad-
verse effects (hypertension, proteinuria, mucosal bleeding, arterial thrombosis) and 
postoperative complications (pelvic infection, delayed wound healing, anastomotic 
leak, fistulas) was relatively high in several trials [21-23]. A better understanding of 
the mechanisms responsible for the disappointing results is necessary before pro-
ceeding to phase III trials. 
ASSESSMENT OF TREATMENT EFFECT
Nowadays there are great expectations on the treatment outcome forecast based 
on biological evidence of heterogeneity which determines the tumor (presence of 
EGFR expression, mutation status of BRAF, dMMR and KRAS). 
Studying KRAS, BRAF and PI3KCA mutations in rectal cancer, Derbel et al. 
have failed to determine the predictors of the outcome of neoadjuvant treatment in 
a group of 98 patients [21]. They concluded that further research on a larger number 
of patients and greater statistical power was needed.
In the last decade, the search for biological markers that predict clinical outco-
mes has shifted toward the microenvironment in which the tumor grows. Gallon 
et al. have found that complete histologic regression occurred significantly more 
frequently in patients with a relative number of lymphocytes in the WBC >26% be-
fore treatment (p=0.023), absolute lymphocyte count >1,634 x109/L (p=0.004), hemo-
globin levels >12.0 g/dL before treatment and clinical findings of N – stage disease 
(p=0.018) [22].
It is possible to find similar claims in the literature about the beneficial effects of 
high levels of circulating lymphocytes on the outcome of the treatment of colorectal 
cancer [25,23]. A biological marker cluster which correlates to clinical outcomes is 
still unknown. 
A further question is if we can obtain an adequate characterization of tumor he-
terogeneity based on clinical observation. According to recently published pooled 
data of randomized trials for locally advanced rectal cancer, there are four groups of 
patients with different tumor heterogeneity (very good, good, bad, ugly) [24]. In cli-
nical trials, all of them were included and there is no reliable endpoint that could be 
used to estimate a beneficial impact of treatment on the overall survival. With rectal 
cancer there are no reliable surrogate endpoints as with other cancers (for exam-
ple: prostate specific antigen is a good surrogate endpoint for survival in prostate 
cancer). The fractions of ugly and bad tumors conceal the treatment benefits of the 
group of good and best, thus preventing us from tailoring therapy on individual ba-
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sis. Due to this inability, many characteristics of colorectal cancer were investigated 
with the intention of discovering possible factors which could predict the outcome 
of neoadjuvant chemoradiotherapy: tumor volume, the level of carcinoembryonic 
antigen (CEA), tumor distance from the anal verge and the period of time between 
the completion of radiotherapy and the definitive surgery [25,26]. 
A complete pathological response is associated with a significantly longer survi-
val, while the N+ lymph node finding after neoadjuvant treatment is an unfavorable 
prognostic indicator regardless of the extent of the primary tumor regression [27,28]. 
The meta-analysis done by Lee et al. has demonstrated that the partial regression of 
tumor is associated with a 50% improvement in the length of disease free survival 
(DFS) and should be considered a favorable prognostic factor [29]. 
PET/CT imaging and the accumulation of FDG in tumor tissue (SUV) could be a 
predictor of tumor regression with 81 % sensitivity and 100 % specificity, with a 90% 
of overall reliability, as demonstrated by Bampo et al. [30]. Early recording showed no 
significant regularity, but the results of the SUV later recording was different between 
patients with complete and incomplete regression at the level of p=0.006. The possibi-
lity of distinguishing complete from incomplete tumor regression before histological 
examination after 6 weeks of radiotherapy (ie. before surgery) could lead to a less 
radical operation (the gospel only crop scar on the intestine and establish continuity) 
or even to a wait-and-see attitude and omitted surgery. The PET/CT with biological 
predictors could help in screening patients and determining the optimal timing for 
accessing surgery or even cancel the previously planned surgery [31].
While it is scientifically proven that complete regression after neoadjuvant trea-
tment significantly prolongs the length of the disease free survival, the prognostic 
value of partial regression is less reliable. Several authors propose their own ways 
of scoring, eg. “tumor regression grade” (TRG) or “rectal cancer regression grade” 
(RCRG) in order to facilitate the further research of this issue. These schemes, if 
proven their reliability in the future, may become more important than the current 
TNM system introduced before the invention of neoadjuvant treatment approach. 
By then, the classification of tumor characteristics according to the TNM system 
should mark the way data are collected (eg, the suffix “c” ‒ clinically, “mr” ‒ by 
NMR, “p” ‒ histologically, “ct” by CT scan). It can somewhat reliably predict the co-
urse of illness in patients with complete tumor regression or those with no response 
to neoadjuvant treatment.
We aim to achieve individual treatment by using the primary and surrogate 
endpoints based on the data obtained from clinical characteristics of patients and 
tumor heterogeneity.
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Statistical prediction models have found multivariate correlations between the 
patient and the tumor characteristics with the outcome. One of the best and simplest 
methods with possible wide application is the interpretation of the prediction model 
with the help of a nomogram or calculator. It is a visual and numerical representati-
on of mathematical relations between individual variables important for predicting 
patients’ outcomes. The first step in compiling nomograms/calculators is gathering 
epidemiological data from large registries of outcomes of malignancies.
Bowles et al. have developed a mathematical model of interactive likelihood of 
5- and 10-year survival by using the data on age, sex, race, tumor differentiation and 
the type of surgery [32]. Covariances were preoperative or postoperative radiothe-
rapy, patients without treatment or stage IV disease. They have created the online 
calculator that can be used with reference to page www.mdanderson.org/rectalcal-
culator. Assessment results are valuable, but only orienteering aid in predicting the 
course of disease and the planning of further treatment or intensity of monitoring. 
The possible subject of further research will be the prognostic significance of 
pelvic lymph node status after partial tumor regression, which will probably help 
us to further stratify the same group of patients and contribute to a better under-
standing of the disease.
DO ALL THE PATIENTS NEED SURGICAL PROCEDURE AFTER  
NEOADJUVANT THERAPY?
The optimal time for surgery after completion of a neoadjuvant radiotherapy is 
difficult to be unambiguously determined. On the basis of published results, there 
are indications that an interval longer than the generally accepted (6 weeks) could 
lead to higher rates of complete regression and operations with sphincter preserva-
tion. Arguments for the expectative attitude could result from the research that has 
already begun. In the group of 70 patients with low rectal tumors located stage T2-
4N0-2M0, Habr-Gama et al. have applied 54 Gy of radiation plus chemotherapy 5-FU/
LV for 6 cycles every 21 days [33]. Complete clinical remission has been observed 
in 68 % of patients. Local recurrence occurred in this group to 17% in the first year, 
10% after the second year, and 57 % is healthy after 5 years of follow-up. A total of 
50 % of the patients was never operated. In these stages of the disease and the speci-
fic position of the tumor it is a significant contribution to the quality of life. Careful 
follow-up enabled a timely “salvage” operation in case of need.
An interesting Rapido study has just started in which two groups were rando-
mized: a control group with conventional neoadjuvant therapy (50 Gy with capeci-
tabine) and an experimental group where the introductory 5x5 Gy of radiation were 
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followed by six cycles of chemotherapy with capecitabine and oxaliplatin. Upon 
completion of the neoadjuvant treatment, all patients will be operated according to 
the principle of TME. The studied outcome will be not only the rate of local recu-
rrence, but especially the impact on overall survival without signs of disease [34].
In a certain way, the above mentioned studies attempt to detect and separate the 
group of patients who have tumors with favorable clinical and pathological charac-
teristics, and those who have already in the epidemiological studies been classified 
into the group of patients with very good and good tumors, as well as ensure them 
a more conservative treatment approach.
RESULTS OF NEOADJUVANT TREATMENT IN UNIVERSITY HOSPITAL 
FOR TUMORS IN ZAGREB, CROATIA
Between January 2011 and December 2014 at the University Hospital for Tumors, 
we have treated 78 patients with T2-4N+ rectal tumors by using two preoperative tre-
atment approaches. We have used short course (SCRT) radiotherapy and long course 
chemoradiotherapy (LCCRT) protocols. Clinical and pathological characteristics of 
all of the patients were defined: gender, age, T and N stages of the disease, and tu-
mor position (distance measured from the anal verge ‒ “low” (0-5 cm), “medium” 
(5-10 cm) and “high” 10-15 cm)). Mesorectal fascia infiltration was assessed with 
the use of magnetic resonance imaging (MRI). Fifteen patients have received a total 
dose of 25 Gy in 5 fractions (short course). In accordance with current guidelines, the 
total treatment duration, including surgical procedure, was 10 days. The remaining 
63 patients have received a total dose of 45-50.4 Gy in 25-28 fractions with concomi-
tant chemotherapy based on fluoropyrimidines. The patients underwent an operati-
on in 6 to 8 weeks after the combined treatment was completed. We have performed 
postoperative analyses of the type of surgical procedure, the degree of histological 
response according to the Ryan classification (degrees of regression – 0, 1, 2, 3) and 
the application of postoperative systemic treatment.
Concomitant chemoradiotherapy induced a complete response in 14.3% patients 
and a partial response in 52.4% patients. In the group of patients treated with short 
course protocol, there was only one patient with a partial response, and none with a 
complete response. In the group of patients treated with a long course chemoradio-
therapy, a statistically significant difference was noted in the T and N stages of the 
disease and in the circumferential resection margin infiltration.
These results are a consequence of treating a larger percent of patients in ad-
vanced stages of the disease with concomitant chemoradiotherapy. Out of 25 pati-
ents with “low” tumors (< 5cm), a local recurrence occurred in one patient treated 
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with SC and in one patient treated with long course chemoradiotherapy. Among the 
patients treated with SCRT, one patient developed local recurrence after 15 mont-
hs of follow-up, while in the LCCRT group six patients developed local recurrence 
after a median follow-up of 14.7 months (range 3–26 months). No statistically si-
gnificant difference in the cumulative incidence of local recurrence (HR = 2.2 CI= 
0,3581-10,273, p=0.4469) was noted when comparing patients treated with SCRT to 
those treated with LCCRT. There was no statistically significant correlation between 
positive lymph nodes and distal metastases, although a positive trend was noted. 
Anal sphincter preservation amounted to 73.3% in the group treated with SCRT, as 
compared to 31.7% in the group treated with LCCRT.
So, a longer patient follow-up, an individualized approach and gathering expe-
rience will enable further improvements in the treatment of these patients.
CONCLUSION
Despite the fact that previous studies have answered some very important qu-
estions, the problem of taking care of patients belonging to neither group remains. 
Consequently, two consensus documents (EURECCA and ESMO) have been produ-
ced, with guidelines on different strategies for staging and treatment with the aim 
of helping clinicians in their everyday work [35,36].
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Sažetak
Suvremeno liječenje karcinoma rektuma
Posljednjih desetljeća svjedoci smo velikog napretka u liječenju karcinoma rektuma. Razvoj 
novih kirurških tehnika, magnetske rezonance kao optimalnog dijagnostičkog alata i novih hi-
stopatoloških tehnika evaluacije reseciranog uzorka omogućili su dio ovih promjena. Ostatak je 
posljedica razvoja sofisticiranih radioterapijskih tehnika koje u kombinaciji s novim citostaticima 
i pametnim lijekovima postižu bolji odgovor tumora na primijenjeno liječenje uz smanjenje tok-
sičnosti. Iako je svaka disciplina doprinijela boljem razumijevanju bolesti, tek je multidisciplinar-
ni pristup omogućio sadašnju razinu uspjeha liječenja. 
Ključne riječi: neoadjuvantna terapija; kratki radioterapijski protokol; dugi radioterapijski pro-
tokol; konkomitatna kemoterapija; patološki kompletni odgovor.
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